Navigation Links
ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
Date:8/11/2008

potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; the market potential for ADVENTRX's product candidates and ADVENTRX's ability to compete in those markets; the scope and validity of patent protection for ADVENTRX's product candidates; patent and non-patent exclusivity covering Navelbine(R) and Taxotere(R); and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

[Tables to Follow]

ADVENTRX Pharmaceuticals, Inc. and Subsidiaries

(A Development Stage Enterprise)

Summary Condensed Consolidated Financial Information

(In 000s except for per share data)

Consolidated

Statement of

Operations Data:

Three months ended Six months ended

June 30, June 30,

2008 2007 2008 2007

(unaudited) (unaudited) (unaudited) (unaudited)

Revenues $500 $- $500 $500

Operating expenses:

Research and

development 4,511 4,240 8,332 7,624

Selling, general

and administrative 2,636 2,006 5,001 4
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
2. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
3. ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference
4. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
5. ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference
6. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
7. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
8. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
9. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
10. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
11. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... York, NY (PRWEB) April 21, 2015 What ... Jessica Parker, Tom Ford and Ted Turner have in common? ... of the 50 Most Powerful Americans 50+. In a 16-page ... Chief of more than 50 magazines and 25 websites, along ... on the power they wield through the unique lens of ...
(Date:4/21/2015)... 21, 2015 Zane Benefits, a software ... its CEO Rick Lindquist has been selected as one ... According to Rick Lindquist, “There is a massive shift ... Benefits’ small business solutions are at its forefront. Our ... Employee Benefit Adviser’s Rising Stars.” , According to the ...
(Date:4/21/2015)... Let's face it; a lot of skin ... and complex routines for hundreds of dollars. Block ... gimmicks, as the sun is the leading cause of skin ... more than just daily sun protection; it is also about ... new Purifying Facial Cleanser and Revitalizing Night ...
(Date:4/21/2015)... April 21, 2015 Quark Software ... a new knowledge management solution that enables large ... of policies and procedures. With Quark Procedure Management, ... content that is easy to save, search and ... to risk and compliance issues. Examples of policies ...
(Date:4/21/2015)... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology ... report results for the first quarter of 2015 on ... market. , The Company will host a conference ... release at 4:30 PM ET. Investors interested in ... at 1.877.407.0993 or use the direct dial-in number 1.201.689.8795. ...
Breaking Medicine News(10 mins):Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 2Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 3Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 4Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 3Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 3Health News:AxoGen, Inc. to Report First Quarter Financial Results on May 5, 2015 2
... Fla. October 24, 2011 Patients in the United ... able to benefit from a new treatment that is already ... The treatment, called collagen crosslinking, improved vision in almost 70 ... clinical trial in Milan, Italy. The treatment is in clinical ...
... Heavy alcohol consumption may be linked to a ... and increased consumption of black tea and fruit are ... three separate studies presented at CHEST 2011, the 77th ... (ACCP), heavy alcohol consumption was related to increased risk ...
... Lung Cancer Mortality Rates , (#1111771, Tuesday, October ... has one of the highest mortality rates in the ... on data from the National Cancer Institute Surveillance, Epidemiology, ... Regional Medical Center in Flint, Michigan and the Mayo ...
... training on a take-home simulator do a better job once ... told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart ... Dr. Lam and a multidisciplinary surgical team developed a kit ... be taken home by trainees to practice a highly technical ...
... reconstruction with tissue from their own abdomen experience significant ... as three weeks after surgery. That is one of ... in Cancer , a peer-reviewed journal of the ... to breast cancer survivors who are contemplating these types ...
... -- While there are challenges, Halloween can still be fun ... enjoy Halloween and enjoy some of the sweets the holiday ... and senior scientist at the University of Alabama at Birmingham ... "We give parents and kids three options and let them ...
Cached Medicine News:Health News:Vitamin B-based treatment for corneal disease may offer some patients a permanent solution 2Health News:Heavy alcohol consumption linked to lung cancer 2Health News:CHEST 2011: Embargoed studies highlight new lung cancer and COPD research 2Health News:CHEST 2011: Embargoed studies highlight new lung cancer and COPD research 3Health News:Heart surgeons-in-training benefit from hands-on homework 2Health News:Advanced post-mastectomy breast reconstruction improves women's psychosocial and sexual well-being 2Health News:Healthy Halloween Advice for Children With Diabetes 2
(Date:4/21/2015)... 21, 2015  TissueGene, Inc. a clinical-stage biopharmaceutical ... the field of cell therapy, today announced the ... of Chief Operating Officer.  Mr. Newman was most ... Clinical Operations at ZIOPHARM Oncology, a ... gene expression, control and cell technologies in the ...
(Date:4/21/2015)... and PARIS and BURLINGTON, N.C. , ... (NYSE: DGX ), the world,s leading provider ... National Institute of Health and Medical Research institution, ... they co-founded to provide scientists and laboratory organizations ... and BRCA2 genetic data. The program,s goal is ...
(Date:4/21/2015)... April 21, 2015 /PRNewswire/ -- Mindray Medical International Limited ("Mindray", ... marketer of medical devices worldwide, today announced that it ... ended Mar 31, 2015 after the U.S. market closes ... earnings conference call at 8:00 AM on May 12, ... 2015 Beijing/Hong Kong Time). Dial-in details ...
Breaking Medicine Technology:TissueGene, Inc. Hires Robert Newman as Chief Operating Officer 2Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 2Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 3Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 4Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 5Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 6Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 7Mindray to Report 2015 First Quarter Financial Results on May 11, 2015 2
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
Used for vascular and non-vascular applications. Tapered fixed core construction provides gradual transition to a flexible,tip. Supplied sterile in peel-open packages. Intended for one-time use....
... Merit Medical is pleased to offer ... The pre-coated, high-performance, InQwire guide wire ... is very lubricious and can help ... available in a wide range of ...
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
Stent delivery with extra rail support...
Medicine Products: